DK0918545T3 - Tumorbehandling - Google Patents

Tumorbehandling

Info

Publication number
DK0918545T3
DK0918545T3 DK97945975T DK97945975T DK0918545T3 DK 0918545 T3 DK0918545 T3 DK 0918545T3 DK 97945975 T DK97945975 T DK 97945975T DK 97945975 T DK97945975 T DK 97945975T DK 0918545 T3 DK0918545 T3 DK 0918545T3
Authority
DK
Denmark
Prior art keywords
compound
vascular compartment
tumor treatment
mammal
following administration
Prior art date
Application number
DK97945975T
Other languages
Danish (da)
English (en)
Inventor
Kenneth Dawson Bagshawe
Original Assignee
Enzacta R & D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzacta R & D Ltd filed Critical Enzacta R & D Ltd
Application granted granted Critical
Publication of DK0918545T3 publication Critical patent/DK0918545T3/da

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97945975T 1996-11-30 1997-11-28 Tumorbehandling DK0918545T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624993.3A GB9624993D0 (en) 1996-11-30 1996-11-30 Tumour therapy
PCT/GB1997/003284 WO1998024478A2 (fr) 1996-11-30 1997-11-28 Therapie tumorale

Publications (1)

Publication Number Publication Date
DK0918545T3 true DK0918545T3 (da) 2000-11-27

Family

ID=10803777

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97945975T DK0918545T3 (da) 1996-11-30 1997-11-28 Tumorbehandling

Country Status (11)

Country Link
EP (1) EP0918545B1 (fr)
JP (1) JP2001505220A (fr)
AT (1) ATE194499T1 (fr)
CA (1) CA2273218A1 (fr)
DE (1) DE69702527T2 (fr)
DK (1) DK0918545T3 (fr)
ES (1) ES2150286T3 (fr)
GB (1) GB9624993D0 (fr)
GR (1) GR3034592T3 (fr)
PT (1) PT918545E (fr)
WO (1) WO1998024478A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9812550D0 (en) * 1998-06-11 1998-08-05 Aepact Ltd Tumour therapy and imaging
CA2471645A1 (fr) * 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Nouveaux immunoconjugues utiles pour le traitement de tumeurs
GB0916749D0 (en) * 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
FI3377103T4 (fi) 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
EP0869818A1 (fr) * 1995-12-29 1998-10-14 AEPACT Limited Agents cytotoxiques

Also Published As

Publication number Publication date
ATE194499T1 (de) 2000-07-15
WO1998024478A2 (fr) 1998-06-11
DE69702527T2 (de) 2001-03-08
PT918545E (pt) 2000-12-29
CA2273218A1 (fr) 1998-06-11
WO1998024478A3 (fr) 1998-07-30
ES2150286T3 (es) 2000-11-16
EP0918545B1 (fr) 2000-07-12
EP0918545A2 (fr) 1999-06-02
JP2001505220A (ja) 2001-04-17
GB9624993D0 (en) 1997-01-15
GR3034592T3 (en) 2001-01-31
DE69702527D1 (de) 2000-08-17

Similar Documents

Publication Publication Date Title
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
PT1223980E (pt) Utilizacao de inibidores de csf-1
MY122383A (en) Cyclic boroproline compounds
DK0988301T3 (da) Imidazolylcykliske acetaler
AU527371B2 (en) Amidine
ES2174953T3 (es) Composiciones dermatologicas que contienen peroxido de benzoilo y un compuesto que reduce la irritacion de la piel.
NZ334691A (en) Compositions of anti-4-1BB antibody effective for immunomodulation and treatment of T-cell autoimmune disease
NO20014415L (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
DK0918545T3 (da) Tumorbehandling
ATE203016T1 (de) Cryptophycine
NO974275L (no) Fremgangsmåte for behandling av tumorer
FI904521A0 (fi) Komposition foer inducering av sammanbindning.
ATE317693T1 (de) Substituierte stilbene mit gefässschädigender aktivität
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
TR200501763T2 (tr) Tedavi ve ilaç tarama yöntemleri
NO20016380L (no) Fremgangsmåte for å forhindre tumorvekst
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
RU92012992A (ru) Способ гормонотерапии раковых больных
WO1996007421A3 (fr) Medicament anti-ulcereux comprenant une proteine ayant une activite de facteur de croissance cellulaire et un inhibiteur de la pompe a protons
ATE332362T1 (de) Gen fuer selektive proliferation
RU95119300A (ru) Средство для лечения длительно незаживающих ран
TW221711B (en) N-AFP monoclonal antibody and method of preparation thereof
SU1545555A1 (ru) Дизамещенные гликолоилгидразоны-β-хлор-β-ферроценилакрилового альдегида, обладающие противовоспалительной активностью